Press release 29 July 2008

The FDA has accepted for filing the registration application for Sublinox

The submitted registration application for Sublinox has been accepted by the FDA as complete for substantive review after initial evaluation. Sublinox contains the well-known active substance zolpidem and is based on Orexo's sublingual technology, involving a rapidly disintegrating tablet placed under the tongue.

Meda AB acquired the exclusive world-wide commercialization rights for Sublinox on April 14, 2008. *"This FDA's acceptance increases the chances for a registration approval during 2009"*, said Anders Lonner, CEO of Meda.

The data supporting the product includes a clinical study in insomnia patients that was completed in October 2007. That study showed that Sublinox induced sleep 30 percent earlier compared to Ambien and that patients remained asleep throughout the night with comparable safety.

"This is an important first step to get Sublinox out on the world markets", said Torbjörn Bjerke, Orexo's President and CEO.

For more information contact:

Meda AB	Anders Larnholt, Vice President Investor Relations
	Tel: +46 (0)709 458 878, E-mail: anders.larnholt@meda.se
Orexo AB	Claes Wenthzel, Executive Vice President & CFO,
	Tel: +46 (0)18-780 88 44, E-mail: claes.wenthzel@orexo.com

MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in 26 countries and has more than 1 500 employees within marketing and sales. Meda's products are sold in about 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.

About Orexo
Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases. Orexo has a broad and competitive late-stage product portfolio, including two marketed products, five products in clinical phase and two undergoing registration. Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange Stockholm, Small Cap (ticker: ORX) www.orexo.com.

Meda AB (publ), corporate ID: 556427-2812
Pipers väg 2A, Box 906, SE-170 09 Solna, Sweden
info@meda.se, www.meda.se, Tel: +46-8-630 19 00. Fax: +46-8-630 19 50